Italian cancer research centre specialising in personalized breast cancer screening, genetic risk assessment, and AI-driven oncology patient monitoring.
IRST is a dedicated cancer research and treatment centre in Meldola, Italy, focused on translational oncology — bridging laboratory science with clinical practice. They contribute as clinical sites in large multinational studies, providing patient cohorts, medical protocol execution, and clinical validation of new cancer screening or monitoring approaches. Their work spans personalized breast cancer risk assessment using genetic markers and imaging, through to digital tools that track cancer patient wellbeing and health recovery after treatment. As a specialized cancer centre rather than a generalist university hospital, they offer deep oncology domain expertise combined with direct access to real patient populations.
IRST participates in MyPeBS (2018–2027), a large international randomized trial comparing personalized risk-based screening to standard mammography, involving genetic polymorphism analysis and individual risk scoring.
In ONCORELIEF (2020–2023), IRST contributed to a digital health platform using AI and big data analytics to track and improve cancer patient wellbeing following treatment.
MyPeBS relies on analysis of genetic polymorphisms to assign individual breast cancer risk scores, indicating IRST's capacity to work with genomic and clinical data in combination.
Their involvement in ONCORELIEF — a project explicitly built on artificial intelligence and big data analytics — signals a move toward computational methods applied to cancer patient management.
IRST's early H2020 work (from 2018) was grounded in clinical and genetic medicine: breast cancer screening protocols, mammography, genetic polymorphisms, and individual risk scoring. This reflects their core identity as a clinical research centre running patient studies with a biological and epidemiological focus. By 2020, their second project shifted sharply toward digital health — AI, big data analytics, and patient wellbeing monitoring — suggesting they are integrating computational tools into their clinical research portfolio. The trajectory is from pure clinical-genetic research toward a hybrid model where digital platforms support oncology patient management.
IRST is moving from traditional clinical trial participation toward digitally-augmented oncology — making them a relevant partner for projects combining clinical cancer expertise with AI, patient-reported outcomes, or remote monitoring technologies.
IRST has participated only as a consortium partner across both H2020 projects, never taking the coordinator role — a pattern typical of clinical research centres that contribute patients, data, and medical expertise rather than leading project management. Despite having only two projects, they have worked with 44 unique partners across 12 countries, suggesting they join large, multinational clinical consortia rather than small bilateral collaborations. This makes them a reliable specialist contributor: they bring clinical depth and patient access, while others handle coordination and technology development.
IRST has built a surprisingly broad network for a two-project participant — 44 unique consortium partners across 12 countries, consistent with involvement in large pan-European clinical trials. Their network is European in scope, likely anchored by academic medical centres and cancer research institutes from across the EU.
IRST is a purpose-built cancer research centre, not a general university hospital or national health authority — this gives them focused oncology expertise and a patient population specifically relevant to cancer research, which is harder to access through generalist partners. Their combination of clinical genetics competence (breast cancer risk scoring, polymorphism analysis) with an emerging digital health track makes them unusually suited for hybrid projects at the intersection of oncology and health technology. For a consortium needing a credible Italian clinical site with a direct oncology mandate, IRST offers both scientific credibility and institutional alignment with cancer-focused research agendas.
